Novozymes A/S (OTCMKTS:NVZMY) Short Interest Down 86.4% in July

Novozymes A/S (OTCMKTS:NVZMY) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 3,603 shares, a decline of 86.4% from the July 15th total of 26,584 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 47,927 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Novozymes A/S

An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B raised its position in Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

Novozymes A/S Trading Down 0.1%

OTCMKTS:NVZMY traded down $0.07 during trading hours on Thursday, reaching $64.19. 20,377 shares of the company were exchanged, compared to its average volume of 71,445. The firm has a market cap of $26.61 billion, a price-to-earnings ratio of 43.37, a PEG ratio of 3.02 and a beta of 0.92. The stock has a 50 day simple moving average of $62.70 and a 200 day simple moving average of $60.45. Novozymes A/S has a 52-week low of $49.90 and a 52-week high of $66.66. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 1.03.

Analyst Ratings Changes

NVZMY has been the topic of several analyst reports. Kepler Capital Markets upgraded Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Zacks Research upgraded Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Novozymes A/S currently has an average rating of “Buy”.

Novozymes A/S Company Profile

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).